Contemporary Burden, Drivers, and Risk‐Factor Control Gaps Across Cardiovascular–Kidney–Metabolic Syndrome Stages in US Adults, 2021 to 2023
Journal of the American Heart Association · 03.11.2026 · 15 (21)
DOI: 10.1161/jaha.126.053440 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 03.11.2026. Verfasst von Sangho Hyun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine Lakeland Regional Health Medical Center Lakeland FL USA. Hauptthemen laut MEDLINE: Metabolic Syndrome, Cardio-Renal Syndrome, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background
Cardiovascular–kidney–metabolic (CKM) syndrome staging integrates adiposity, metabolic dysfunction, chronic kidney disease, and cardiovascular disease. Contemporary national estimates of CKM stage distribution, stage drivers, and treatment gaps are needed to inform implementation of the CKM framework.
Methods
We analyzed adults aged ≥20 years in the National Health and Nutrition Examination Survey 2021 to 2023 fasting subsample. CKM stage was assigned hierarchically using American Heart Association CKM staging criteria. We estimated survey‐weighted CKM stage prevalence, national population counts, stage‐specific drivers, and risk‐factor control and treatment gaps across stages 2 through 4.
Results
The analytic sample included 2958 adults, representing 245.2 million US adults. Overall, 26.4 million adults (10.8%) were stage 0, 56.8 million (23.2%) stage 1, 125.9 million (51.3%) stage 2, 13.4 million (5.5%) stage 3, and 22.7 million (9.3%) stage 4. Stage ≥1 was present in 89.2%, stage ≥2 in 66.1%, and advanced CKM (stages 3–4) in 14.7%. Among stage 1 adults, 85.1% had adiposity and 49.2% had prediabetes. Among adults with stage 2 CKM, hypertension (72.0%), metabolic syndrome (56.1%), and hypertriglyceridemia (41.9%) were common drivers. Among adults with stage 3 CKM, 95.8% met the Predicting Risk of Cardiovascular Disease Events 10‐year cardiovascular disease risk criterion. Risk‐factor control and treatment gaps were common across stages 2 through 4, including blood pressure ≥130/80 mm Hg in 50.3% to 66.9%, lipid‐lowering therapy nonuse among eligible adults in 30.1% to 59.2%, and low‐density lipoprotein cholesterol above the target in 64.5% to 73.9%.
Conclusions
CKM syndrome affects most US adults, with stage‐specific drivers and persistent risk‐factor control and treatment gaps. These findings provide contemporary benchmarks for CKM surveillance and implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine Lakeland Regional Health Medical Center Lakeland FL USA.
ORCID-Profile: Sangho Hyun, John Iwaniec, Sana Khan, Anas Bizanti
Zitieren
APA
Hyun, S., Sze, C. H., Khan, T., Iwaniec, J., Khan, S., & Bizanti, A. (2026). Contemporary Burden, Drivers, and Risk‐Factor Control Gaps Across Cardiovascular–Kidney–Metabolic Syndrome Stages in US Adults, 2021 to 2023. Journal of the American Heart Association, 15(21). https://doi.org/10.1161/jaha.126.053440
Vancouver
Hyun S, Sze CH, Khan T, Iwaniec J, Khan S, Bizanti A. Contemporary Burden, Drivers, and Risk‐Factor Control Gaps Across Cardiovascular–Kidney–Metabolic Syndrome Stages in US Adults, 2021 to 2023. Journal of the American Heart Association. 2026;15(21). doi:10.1161/jaha.126.053440
BibTeX
@article{Hyun2026,
author = {Hyun, Sangho and Sze, Chia-Hung and Khan, Tughral and Iwaniec, John and Khan, Sana and Bizanti, Anas},
title = {Contemporary Burden, Drivers, and Risk‐Factor Control Gaps Across Cardiovascular–Kidney–Metabolic Syndrome Stages in US Adults, 2021 to 2023},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {21},
doi = {10.1161/jaha.126.053440}
}
EUVIMED